Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer von Felip, Enriqueta, Metro, Giulio, Tan, Daniel S.W., Wolf, Juergen, Mark, Michael, Boyer, Michael, Hughes, Brett G.M., Bearz, Alessandra, Moro-Sibilot, Denis, Le, Xiuning, Puente, Javier, Massuti, Bartomeu, Tiedt, Ralph, Wang, Yingying, Xu, Chao, Mardjuadi, Feby I., Cobo, Manuel

Volltext

A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma von Santoro, Armando, Assenat, Eric, Yau, Thomas, Delord, Jean-Pierre, Maur, Michela, Knox, Jennifer, Cattan, Stephane, Lee, Kyung-Hun, Del Conte, Gianluca, Springfeld, Christoph, Leo, Elisa, Xyrafas, Alexandros, Fairchild, Lauren, Mardjuadi, Feby, Chan, Stephen L.

Volltext

Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of... von Mok, Tony S. K., Cortinovis, Diego Luigi, Majem, Margarita, Johnson, Melissa Lynne, Mardjuadi, Feby Ingriani, Zhao, Xuan, Siripurapu, Sagar Vidya, Jiang, Zhiqiang, Wolf, Juergen

Volltext

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the... von Jimeno, Antonio, Machiels, Jean‐Pascal, Wirth, Lori, Specenier, Pol, Seiwert, Tanguy Y., Mardjuadi, Feby, Wang, Xiaodong, Kapp, Amy V., Royer‐Joo, Stephanie, Penuel, Elicia, McCall, Bruce, Pirzkall, Andrea, Clement, Paul M.

Volltext

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the... von Jimeno, Antonio, Machiels, Jean-Pascal, Wirth, Lori, Specenier, Pol, Seiwert, Tanguy Y, Mardjuadi, Feby, Wang, Xiaodong, Kapp, Amy V, Royer-Joo, Stephanie, Penuel, Elicia, McCall, Bruce, Pirzkall, Andrea, Clement, Paul

Volltext

A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epitheli... von Calvo, Emiliano, Gil-Martin, Marta, Machiels, Jean-Pascal H., Rottey, Sylvie, Cubillo, Antonio, Salazar, Ramon, Mardjuadi, Feby Ingriani, Geboes, Karen Paula, Ellis, Christopher, Beadle, John William, Blanc, Christine

Volltext

Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer von Mardjuadi, Feby Ingriani, Carrasco, Javier, Coche, Jean-Charles, Sempoux, Christine, Jouret-Mourin, Anne, Scalliet, Pierre, Goeminne, Jean-Charles, Daisne, Jean-François, Delaunoit, Thierry, Vuylsteke, Peter, Humblet, Yves, Meert, Nicolas, van den Eynde, Marc, Moxhon, Anne, Haustermans, Karin, Canon, Jean-Luc, Machiels, Jean-Pascal

Volltext

Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer von Mardjuadi, Feby, Medioni, Jacques, Kerger, Joseph, D’Hondt, Lionel, Canon, Jean-Luc, Duck, Lionel, Musuamba, Flora, Oudard, Stephane, Clausse, Marylene, Moxhon, Anne, Machiels, Jean-Pascal

Volltext

Phase II trial of preoperative radiotherapy (RT) and panitumumab (PAN) in KRAS wild type (wt) rectal cancer (RC) von Mardjuadi, Feby Ingriani, Canon, Jean-Luc, Coche, Jean-Charles, Jouret-Mourin, Anne, Sempoux, Christine, Goeminne, Jean-Charles, Delaunoit, Thierry, Carrasco, Javier, Vuylsteke, Peter, Humblet, Yves, Meert, Nicolas, Van den Eynde, Marc, Moxhon, Anne, Machiels, Jean-Pascal H.

Volltext